openPR Logo
Press release

High Potency Active Pharmaceutical Ingredient (HPAPI) Market Estimated to Expand at a CAGR of 8.3% through 2023

04-18-2018 08:02 AM CET | Health & Medicine

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
High Potency Active Pharmaceutical Ingredient (HPAPI) Market

The booming oncology research and rising cases of cancer, diabetes, and other cardiovascular diseases have created a sizeable demand for dedicated treatments, thereby driving the high potency active pharmaceutical ingredient (HPAPI) market. The HPAPI market stood at a valuation of US$2.64 bn in 2014. The cost containment strategies adopted by companies through outsourcing are favoring market growth. This has brought down the cost of drugs drastically, making them affordable to a larger audience. The positive result of this trend is seen on the increased focus of companies on drug development and commercialization. As a result of these favorable trends, the HPAPI market is projected to be worth US$25.11 bn by 2023. Between 2015 and 2023, the market is expected to expand at a CAGR of 8.3%.

View Report-
https://www.transparencymarketresearch.com/high-potency-active-pharmaceutical-Ingredients-market.html

A promising pipeline of targeted therapeutic drugs will also help the market progress in the coming years. These drugs have minimal side effects and impact targeted areas, thereby helping the patient to recover faster with no lingering after effects. These positive perceptions surrounding HPAPIs combined with the near-expiration dates of blockbuster drugs, which will offer several generic drug manufacturers a chance to offer affordable drugs, will further the market’s growth. Consistent research and development to mimic branded drugs will create alternative and cost-effective treatments for patients across the globe, thereby augmenting the growth rate of the market.

Emerging Nations in Asia Pacific Becoming Hubs of Generic Drug Manufacturing, to Aid HPAPI Market Growth

Brochure Download-
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=748

Asia Pacific is the expected to be the most lucrative market for high potency active pharmaceutical ingredients due to the soaring contract manufacturing activities in the region. Analysts predict that China will surpass Japan’s current share of 40% in the Asia Pacific market by the end of 2025. This change will be a result of low labor costs in China, well-equipped manufacturing plants, and supportive foreign exchange policies.

India will also be an upcoming high potency active pharmaceutical ingredients market due to the growing concentration of pharmaceutical manufacturing activities in the country. In the forecast period, the country is expected to be the hub for generic drug manufacturing. The growing investments by key players in India are also anticipated to boost this market in the near future. During the forecast period of 2015 to 2023, the Asia Pacific HPAPI market is expected to rise at a CAGR of 10.1%.

Request A Sample-
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=748

Oncology Drugs Show Maximum Demand

The oncology drugs segment has been the leading segment of the global high potency active pharmaceutical ingredient market. This segment is expected to expand at CAGR of 8.3% during the forecast period. The introduction of innovative drugs is the primary growth driver for the oncology segment. Analysts predict that the patent expiry of blockbuster drugs such as Herceptin, Rituxan, and Humira will pave the way for generic drug manufacturers, thereby making these drugs affordable to a wide number of patients.

Some of the leading players operating in the global high potency active pharmaceutical ingredient market are WuXi AppTec, Sigma-Aldrich Co. LLC, Pfizer, Inc., Sandoz International GmbH, Novasep, Lonza Group, Dr. Reddy's Laboratories, Cambrex Corporation, and Alkermes plc. The fragmented nature of this market will result in strategies to acquire and merge with regional players to gain the first-mover advantage.

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us-
90 State Street,
Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release High Potency Active Pharmaceutical Ingredient (HPAPI) Market Estimated to Expand at a CAGR of 8.3% through 2023 here

News-ID: 1020725 • Views:

More Releases from Transparency Market Research

Hypodermic Needles Market to Reach US$ 7.9 Billion by 2036 on Rising Injectable Drug Demand
Hypodermic Needles Market to Reach US$ 7.9 Billion by 2036 on Rising Injectable …
The global hypodermic needles market was valued at approximately US$ 4.2 billion in 2025 and is projected to reach around US$ 7.9 billion by 2036, expanding at a CAGR of nearly 5.8% from 2026 to 2036, driven by the rising prevalence of diabetes, cancer, and chronic diseases, growing demand for injectable drugs and biologics, and the expansion of global vaccination and immunization programs; increasing adoption of safety-engineered and disposable needles,
Connected Car Market to Reach US$ 467.2 Billion by 2036, Driven by Rising Adoption of ADAS and Expansion of 5G & V2X Connectivity
Connected Car Market to Reach US$ 467.2 Billion by 2036, Driven by Rising Adopti …
The global connected car market is entering a high-growth phase as vehicles increasingly evolve into software-defined, data-driven mobility platforms. Valued at US$ 100.8 billion in 2025, the market is projected to reach an impressive US$ 467.2 billion by 2036, expanding at a robust CAGR of 12.3% from 2026 to 2036. This growth is fueled by rapid advancements in automotive connectivity, rising consumer demand for intelligent features, and strong integration of
Density Gradient Media Market to Reach US$ 4.1 Billion by 2036, Driven by Rapid Growth in Cell Therapy and Infectious Disease Diagnostics | Latest Report TMR
Density Gradient Media Market to Reach US$ 4.1 Billion by 2036, Driven by Rapid …
The global density gradient media market was valued at US$ 1.4 Billion in 2025 and is projected to reach US$ 4.1 Billion by 2036, expanding at a robust CAGR of 10.2% from 2025 to 2036. The market's rapid growth is primarily driven by increasing demand for rapid infectious disease screening, expanding cell therapy and immunology research, and continuous technological advancements improving sensitivity and multiplexing in laboratory workflows. Access key findings and
Functional Coffee Market Expanding at 7.6% CAGR Through 2035 - By Product Type / By Function | Europe • North America • Asia Pacific
Functional Coffee Market Expanding at 7.6% CAGR Through 2035 - By Product Type / …
The global functional coffee market was valued at US$ 21.5 Bn in 2024 and is projected to reach US$ 48.1 Bn by 2035, expanding at a compound annual growth rate (CAGR) of 7.6% from 2025 to 2035. This steady growth trajectory reflects the strong convergence of coffee consumption habits with rising demand for functional and wellness-oriented beverages. Functional coffee has transitioned from a niche category to a mainstream product offering,

All 5 Releases


More Releases for HPAPI

Cytotoxic Drugs and HPAPI Manufacturing Market
Cytotoxic Drugs and HPAPI Manufacturing Market worth $27.1 Bn by 2031 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Cytotoxic Drugs and HPAPI Manufacturing Market- (Type of Product (HPAPI and highly potent finished dosage form), Company Size (Small, Mid-sized, Large, Very Large), Scale of Operation (Preclinical, clinical, commercial), Type of Molecule (Small molecules, biologics), Type of Highly Potent
HPAPI Market Player Profiling, Forecast till 2028
According to Ameco Research 'HPAPI Market report, the analysts took this into account when estimating the HPAPI Market size and CAGR for the respective industry. The report's author has thoroughly examined the market and concluded that the HPAPI Market 's growth will level off in the coming years. In addition to that, the prominent qualitative information added in the report includes HPAPI Market trends, segmentation, key companies, SWOT, PORTER and
HPAPI Market Size Forecast till 2028
According to Ameco Research 'HPAPI Market report, the analysts took this into account when estimating the HPAPI Market size and CAGR for the respective industry. The report's author has thoroughly examined the market and concluded that the HPAPI Market 's growth will level off in the coming years. In addition to that, the prominent qualitative information added in the report includes HPAPI Market trends, segmentation, key companies, SWOT, PORTER and
HPAPI Market: Opportunities and Challenges
The global HPAPIs Market is projected to register a CAGR of 8.7% during the forecast period (2018-23). The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies and growing focus on precision medicine. However, factors such as the requirement of large investments, discrepancies in HPAPI banding
New Technologies for HPAPI Manufacturing and Containment
SMI Reports: With new technologies becoming available for the pharmaceutical industry, the HPAPI market is utilising these new innovations to simplify manufacturing processes reducing powder exposure and allowing a semi-continuous production. At this year's HPAPI USA Conference emerging manufacturing technologies will be one of the key points to be discussed along with containment issues, disaster management, Oncology Antibody-Drug Conjugates (ADCs) and staff training procedures. Key highlights include: Alternative HPAPI manufacturing technologies to
The Latest Innovations in HPAPI Manufacturing Technologies
SMi’s inaugural Highly Potent Active Pharmaceutical Ingredients USA Conference, will focus on the latest innovative manufacturing technologies with a special spotlight presentation on effective and safe containment solutions for biologics based HPAPIs, along with cleaning and cross contamination requirements. Keith Jensen, Owner and Consultant at Keith Jensen Consulting, previously at Novartis-MIT Center for Continuous Manufacturing, discusses alternative HPAPI manufacturing technologies to reduce powder exposure and improve safety enabling continuous manufacturing. Other